Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 6/20 | 0.67 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.58 |
| ▸ | CDK2 | P24941 | 2/20 | 0.58 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.53 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20119392 | 0.84 | CDK1 (0.53) | CDK1CDK2ADORA3ADORA2AADORA2B | |
| SCHEMBL20119629 | 0.81 | CDK1 (0.72) | CDK1YTHDC1ADORA3ADORA2AADORA2B | |
| SCHEMBL17933825 | 0.81 | SMN1; SMN2 (0.58) | CDK1CCNB2CCNB1CCNB3SMN1; SMN2 | |
| SCHEMBL20119375 | 0.80 | YTHDC1 (0.62) | CDK1YTHDC1ADORA3ADORA2AADORA2B | |
| SCHEMBL6820915 | 0.80 | ADORA3 (0.57) | CDK1CCNE2CCNE1CDK2ADORA3 | |
| SCHEMBL8010398 | 0.80 | CDK1 (1.00) | CDK1CCNE2CCNE1CDK2YTHDC1 | |
| SCHEMBL20119380 | 0.79 | HTT (0.54) | CDK1YTHDC1ADORA3ADORA2AADORA2B | |
| SCHEMBL18587976 | 0.77 | YTHDC1 (0.59) | YTHDC1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL29664960 | 0.77 | YTHDC1 (0.59) | YTHDC1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL20119336 | 0.77 | HTT (0.52) | CDK1YTHDC1ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | KYOTO UNIVERSITY (JP) | 2024-07-02 | — | — | US | disclosed |
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | KYOTO UNIVERSITY (JP) | 2024-07-02 | — | — | US | disclosed |
| US-20210205314-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | KYOTO UNIVERSITY (JP) | 2021-07-08 | — | — | US | disclosed |
| US-20200113907-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | KYOTO UNIVERSITY (JP) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205314-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | RBM17, SFPQ, HNRNPAB | CDK1 3881/4885CCNE2 4187/4885CCNE1 4274/4885 |
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | RBM17, SFPQ, HNRNPAB | CDK1 3881/4885CCNE2 4187/4885CCNE1 4274/4885 |
| US-20200113907-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | RBM17, SFPQ, HNRNPAB | CDK1 3881/4885CCNE2 4187/4885CCNE1 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.